CN102026643A - 法舒地尔化合物的用途、方法及其药物组合物 - Google Patents

法舒地尔化合物的用途、方法及其药物组合物 Download PDF

Info

Publication number
CN102026643A
CN102026643A CN2009801229640A CN200980122964A CN102026643A CN 102026643 A CN102026643 A CN 102026643A CN 2009801229640 A CN2009801229640 A CN 2009801229640A CN 200980122964 A CN200980122964 A CN 200980122964A CN 102026643 A CN102026643 A CN 102026643A
Authority
CN
China
Prior art keywords
fasudil
compound
injection
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2009801229640A
Other languages
English (en)
Other versions
CN102026643B (zh
Inventor
肖保国
丁晶
吕传真
姚小青
孙长海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Chase Sun Pharmaceutical Co Ltd
Original Assignee
Tianjin Chase Sun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Chase Sun Pharmaceutical Co Ltd filed Critical Tianjin Chase Sun Pharmaceutical Co Ltd
Priority to CN2009801229640A priority Critical patent/CN102026643B/zh
Publication of CN102026643A publication Critical patent/CN102026643A/zh
Application granted granted Critical
Publication of CN102026643B publication Critical patent/CN102026643B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明提供一种法舒地尔的新用途，即法舒地尔在诱导成年脑神经干细胞再生和/或保护神经功能以及预防和/或治疗与神经元损伤和/或死亡相关疾病中的用途。本发明提供的法舒地尔具体用途包括在制备用于诱导成年脑神经干细胞再生和/或保护神经功能的药物中的用途，制备用于预防和/或治疗与神经元损伤和/或死亡相关疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN2009801229640A 2008-06-26 2009-05-11 法舒地尔化合物的用途、方法及其药物组合物 Active CN102026643B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009801229640A CN102026643B (zh) 2008-06-26 2009-05-11 法舒地尔化合物的用途、方法及其药物组合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200810126351A CN101612157A (zh) 2008-06-26 2008-06-26 法舒地尔诱导成年脑内源性神经干细胞再生的用途
CN200810126351.1 2008-06-26
CN2009801229640A CN102026643B (zh) 2008-06-26 2009-05-11 法舒地尔化合物的用途、方法及其药物组合物
PCT/CN2009/000509 WO2009155777A1 (zh) 2008-06-26 2009-05-11 法舒地尔化合物的用途、方法及其药物组合物

Publications (2)

Publication Number Publication Date
CN102026643A true CN102026643A (zh) 2011-04-20
CN102026643B CN102026643B (zh) 2013-05-01

Family

ID=41443982

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200810126351A Pending CN101612157A (zh) 2008-06-26 2008-06-26 法舒地尔诱导成年脑内源性神经干细胞再生的用途
CN2009801229640A Active CN102026643B (zh) 2008-06-26 2009-05-11 法舒地尔化合物的用途、方法及其药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200810126351A Pending CN101612157A (zh) 2008-06-26 2008-06-26 法舒地尔诱导成年脑内源性神经干细胞再生的用途

Country Status (2)

Country Link
CN (2) CN101612157A (zh)
WO (1) WO2009155777A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2644238T3 (es) 2012-03-12 2017-11-28 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Inhibidores de rho-quinasas para uso en el tratamiento de la esclerosis lateral amiotrófica
CN102973571A (zh) * 2012-12-12 2013-03-20 天津红日药业股份有限公司 法舒地尔的新用途
CN104557897B (zh) * 2014-04-10 2017-10-27 中山大学 法舒地尔‑硫辛酸二联体的合成及其应用
CN104983704A (zh) * 2015-08-13 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种改善脑血管痉挛的药物盐酸法舒地尔组合物片剂
CN105055332A (zh) * 2015-09-10 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗缺血性脑血管疾病的药物盐酸法舒地尔组合物干混悬剂
JP2023509970A (ja) 2020-01-09 2023-03-10 ウールジー・ファーマシューティカルズ・インコーポレイテッド 皮質性認知症に関連する徘徊を治療する方法
EP4125879A4 (en) 2020-03-25 2024-04-03 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF SPATIO-TEMPORAL DISORIENTATION ASSOCIATED WITH PROTEINOPATHY
WO2022086581A1 (en) 2020-10-22 2022-04-28 Woolsey Pharmaceuticals, Inc Methods of treating 4-repeat tauopathies
CN113440649A (zh) * 2021-05-31 2021-09-28 温州医科大学 一种用于定向诱导轴突再生的纺丝膜支架
CA3236462A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
CN1729985A (zh) * 2005-08-02 2006-02-08 吴良信 盐酸法舒地尔注射液及其制备方法

Also Published As

Publication number Publication date
CN102026643B (zh) 2013-05-01
CN101612157A (zh) 2009-12-30
WO2009155777A1 (zh) 2009-12-30

Similar Documents

Publication Publication Date Title
CN102026643A (zh) 法舒地尔化合物的用途、方法及其药物组合物
KR102633530B1 (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
CN111225911B (zh) 用于治疗血液病的化合物和组合物
CN109641838A (zh) Cxcr4抑制剂及其用途
CN101849943A (zh) 使用HIFα稳定剂的改进的贫血治疗
ES2257768T3 (es) Antagonistas de neurotropina para el tratamiento de epilepsia, enfermedad de alzheimer y el dolor.
EA013591B1 (ru) Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
BR112021014112A2 (pt) Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo
CN101605552A (zh) 神经元前体细胞用于治疗中枢神经系统损伤的用途
BR112021006578A2 (pt) inibidor de aurora a quinase para uso no tratamento de neuroblastoma
WO2021169974A1 (zh) 一种抗双重打击淋巴瘤的联合用药物组合物及其应用
CN108703968B (zh) 左旋千金藤啶碱用于抑制或治疗转移性乳腺癌的用途
CN107184572A (zh) 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用
JP4232866B2 (ja) 細胞障害抑制剤
CN110314222A (zh) 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用
CN114010631B (zh) 含笑内酯及其衍生物在创伤性颅脑损伤治疗中的应用
TW201206457A (en) Reishi polysaccharide-based compositions and methods for treatment of cancer
CN110051842A (zh) 诱导肿瘤细胞转变为神经元样细胞以抑制肿瘤生长的制剂
CN107880109A (zh) 一种促红细胞生成素来源肽及其制备方法和用途
CN115010790A (zh) 纳米小肽fg及其在制备治疗及预防眼底血管疾病药物中的应用
CN102633668B (zh) 化合物在转录因子失调相关疾病的治疗药物中的应用
CN105963287B (zh) 复方组合物及其医药用途
CN108904510A (zh) 地塞米松用于抑制或治疗胰腺癌的用途
CN110709079A (zh) 包含1，2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
CN104902891B (zh) 治疗和预防创伤性脑损伤性神经元损害的组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant